Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00242_DB01656> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00242_DB01656 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00242_DB01656 label "DDI between Cladribine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. [drugbank_resource:DB00242_DB01656]" assertion.
- drugbank_resource:DB00242_DB01656 identifier "drugbank_resource:DB00242_DB01656" assertion.
- drugbank_resource:DB00242_DB01656 title "DDI between Cladribine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible." assertion.